Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

  title={Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.},
  author={Richard A. Rudick and William H. Stuart and Peter A. Calabresi and Christian Confavreux and Steven L. Galetta and Ernst-Wilhelm Radue and Fred D. Lublin and Bianca Weinstock-Guttman and Daniel R Wynn and Frances Lynn and Michael A. Panzara and Alfred W. Sandrock},
  journal={The New England journal of medicine},
  volume={354 9},
BACKGROUND Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies. METHODS We randomly assigned 1171 patients who, despite interferon beta-1a therapy, had had at least one relapse during the 12-month period before randomization to receive continued interferon beta-1a… 

Figures and Tables from this paper

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.

How effective is natalizumab as second‐line treatment for multiple sclerosis in daily clinical praxis?

Two papers report the experience with natalizumab after re-introduction of the drug as a second-line therapy in patients with rapidly evolving severe relapsing remitting MS.

Clinical efficacy and benefit of natalizumab

The purpose of this paper is to review evidence for the efficacy of natalizumab, and put its use in MS into perspective.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Natalizumab and the role of α4-integrin antagonism in the treatment of multiple sclerosis

Natalizumab monotherapy 300 mg intravenous every 4 weeks reduced the risk of sustained disability progression by 42% and annualized relapse rate by 68% over 2 years (both p < 0.001 versus placebo).

Natalizumab in the treatment of multiple sclerosis

Natalizumab is now considered second-line therapy for patients who have failed first-line agents such as interferon or glatiramer acetate, and patients and providers must work together to carefully decide if potential benefits outweigh these rare but potentially devastating complications.

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis

Evidence for its efficacy and safety in relapsing–remitting multiple sclerosis is explored; autoimmunity is the most concerning; within Phase III studies, thyroid disorders and immune thrombocytopenic purpura were reported in patients taking alemtuzumab and interferon beta-1a, respectively.

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks

  • B. Singer
  • Medicine, Psychology
    Therapeutic advances in neurological disorders
  • 2017
To optimize appropriate selection of natalizumab for patients with relapsing MS, however, a thorough understanding of individual patient risk factors for PML or other adverse events is also required.

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

In the FTY group the ARR tended to depend on the time interval between discontinuation of NAT and initiation of FTY, and most relapses in the F TY group occurred just before or within 8 weeks after starting FTY.



A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.

A controlled trial of natalizumab for relapsing multiple sclerosis.

In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

The MRI results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients and support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans and appearance of new lesions.

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Starting treatment with interferon beta-1a at the time of a first demyelinating event is beneficial for patients with brain lesions on MRI that indicate a high risk of clinically definite multiple sclerosis.

Defining interferon beta response status in multiple sclerosis patients.

It was found that subgroups with high on-study relapse numbers had more disease progression, differences between responder subgroups were similar in the IFN-beta1a and placebo arms and Baseline characteristics failed to account for differential outcome.

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

The relationship between increased CSF IL- 10 and response to therapy suggests that induction of IL-10 is a mechanism underlying IFNβ-1a effects in MS patients.

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

It is demonstrated that copolymer 1 treatment can significantly and beneficially alter the course of relapsing-remitting multiple sclerosis in a well-tolerated fashion.

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

Interferon beta-1a is beneficial when initiated at the first clinical demyelinating event in patients with brain magnetic resonance imaging evidence of subclinical demYelination and the beneficial effect is present for optic neuritis, brainstem-cerebellar syndromes, and spinal cord syndrome.